Thiazolidinediones for Diabetes: Evidence and Outcomes

Ver informe de evidencia

Evidence on outcomes studied for Thiazolidinediones

Evidence related to thiazolidinedione therapies in diabetes studies.

Crea tu Evidence Workspace

Guarda evidencia sobre los temas que te importan.

Studies

Evidence Pairs

Moderate Evidence

Evidence Strength: 63/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Thiazolidinediones evidence appears to center on HbA1c.

Among 14 indexed studies and 1 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 5 evidence pairs - 10 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsGenerally consistentModerate evidence

HbA1c

7 studies

EvidenceScore™

83/100

ConsistencyScore™

100/100

Proportion achieving HbA1c <7.0%

4 studies

EvidenceScore™

79/100

ConsistencyScore™

73/100

Evidence Snapshot

Studies

Interventions

Outcomes

Across 2 studies, Pioglitazone shows a consistent strong positive signal for BMI.

2 studies

EvidenceScore™: 69/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Proportion achieving HbA1c <7.0% is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Proportion achieving HbA1c <7.0%

Liver stiffness measure

Proportion achieving HbA1c <7.0%

4 studies

EvidenceScore™

79/100

ConsistencyScore™

73/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 5 evidence pairs - 9 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Liver stiffness measure may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Liver stiffness measure

Proportion achieving HbA1c <7.0%

Liver stiffness measure

3 studies

EvidenceScore™

79/100

ConsistencyScore™

67/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 5 evidence pairs - 8 studies

View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Preguntas respondidas por la evidencia

What outcomes has Thiazolidinediones been studied for?

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure are among the most studied areas in relation to Thiazolidinediones.

Emerging Evidence · Consistency cannot yet be determined from the available evidence. · 14 studies · 14 RCTs

View top evidence signals ↓

HbA1c · Strong · 7 studies
Proportion achieving HbA1c <7.0% · Strong · 4 studies
Liver stiffness measure · Strong · 3 studies

Do Thiazolidinediones lower HbA1c?

Thiazolidinediones appear to lower HbA1c.

Strong Evidence · Results are consistent across studies. · 7 studies · 7 RCTs

View top evidence signals ↓

HbA1c · Strong · 7 studies

Which outcomes have the strongest evidence for Thiazolidinediones?

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure have the strongest available evidence signals for Thiazolidinediones.

Strong Evidence · Results are consistent across studies. · 10 studies · 10 RCTs

View top evidence signals ↓

HbA1c · Strong · 7 studies
Proportion achieving HbA1c <7.0% · Strong · 4 studies
Liver stiffness measure · Strong · 3 studies

Where does Thiazolidinediones need more research?

BMI, Fasting Plasma Glucose (FPG), and Adiponectin need more research in relation to Thiazolidinediones.

Moderate Evidence · Results are consistent across studies. · 7 studies · 7 RCTs

View top evidence signals ↓

Adiponectin · Moderate · 2 studies
BMI · Moderate · 2 studies
Fasting Plasma Glucose (FPG) · Moderate · 2 studies

How does Thiazolidinediones compare across studied outcomes?

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure have available evidence for Thiazolidinediones, but the comparison requires review of the underlying studies.

Strong Evidence · Results are consistent across studies. · 10 studies · 10 RCTs

View top evidence signals ↓

HbA1c · Strong · 7 studies
Proportion achieving HbA1c <7.0% · Strong · 4 studies
Liver stiffness measure · Strong · 3 studies

Browse all questions about Thiazolidinediones

Overall Evidence Signals

Among 14 indexed studies and 1 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.